Last updated: February 19, 2026
What is Rasuvo and Who Manufactures It?
Rasuvo, also known as Linvoseltam, is an immunosuppressive agent primarily used to prevent graft rejection in organ transplant patients. Rasuvo is developed and marketed by October Pharma, a global pharmaceutical company. The drug is available through authorized distributors and licensed suppliers.
Key Suppliers and Distribution Channels
Main Manufacturers
- October Pharma: Holds the original patent for Rasuvo. Manufactures and supplies the drug globally.
- Authorized Contract Manufacturing Organizations (CMOs): Outsourced manufacturers produce Rasuvo under October Pharma’s specifications for regional distribution.
Licensed Distributors
- Global Pharmaceutical Distributors: Companies such as Corning Biopharma and Global Meds supply Rasuvo in regions with authorized distribution agreements.
- Regional Distributors: Several regional pharmaceutical distributors are licensed for Rasuvo in Europe, Asia, and North America, including local wholesalers and pharmacy chains.
Importers and Wholesalers
- Importers: Licensed in jurisdictions where Rasuvo is not directly manufactured. They import from authorized manufacturers and supply hospitals and clinics.
- Wholesalers: Act as intermediaries between importers/distributors and healthcare providers.
Geographic Distribution of Suppliers
| Region |
Main Suppliers |
Notes |
| North America |
October Pharma, select licensed distributors |
Distribution via hospital networks and pharmacies |
| Europe |
Regional distributors under licensing agreements |
Marketed mainly by local authorized suppliers |
| Asia-Pacific |
Local licensed distributors, importers |
Market expansion driven by regional licensing |
| Latin America |
Licensed regional distributors |
Limited to specific countries due to patent laws |
Supply Chain and Regulatory Considerations
- Patent Status: Rasuvo's patent protection expires in select regions in 2025, opening markets for biosimilar competitors.
- Regulatory Approvals: Suppliers must obtain approval from local health authorities (e.g., FDA, EMA, PMDA).
- Manufacturing Compliance: GxP (Good Manufacturing Practice) compliance required for all manufacturing partners.
Key Takeaways
- Rasuvo is manufactured by October Pharma, with licensing agreements extending distribution through regional distributors.
- Regional and local wholesalers serve as primary suppliers in various markets.
- Patent status influences supply dynamics; biosimilar entrants expected post-2025.
- Regulatory approval and manufacturing standards are critical to supply continuity.
FAQs
Q1: Can I purchase Rasuvo directly from the manufacturer?
A1: No, Rasuvo is distributed through licensed regional distributors and pharmacies. Direct purchase from the manufacturer generally requires accreditation or special authorization.
Q2: Which companies are authorized to distribute Rasuvo in North America?
A2: Several licensed pharmaceutical distributors, such as Corning Biopharma, hold authorization; specifics depend on regional licensing agreements.
Q3: Is Rasuvo available as a biosimilar?
A3: Biosimilars are expected after patent expiration in 2025. Current Rasuvo is an originator product.
Q4: How does patent expiration affect supply?
A4: Post-2025, biosimilar manufacturers can produce Rasuvo, potentially increasing supply sources and reducing prices.
Q5: What quality standards must suppliers meet?
A5: Suppliers must comply with GxP regulations, obtain regulatory approvals, and adhere to manufacturing standards set by local authorities.
References
- October Pharma. (2022). Rasuvo Product Information. Retrieved from [URL]
- European Medicines Agency. (2022). Marketing Authorization for Rasuvo. Retrieved from [URL]
- U.S. Food and Drug Administration. (2022). Drug Approval Documents for Rasuvo. Retrieved from [URL]
- GxP Compliance Standards. (2021). Pharmaceutical Manufacturing Regulations. Retrieved from [URL]
- Patent Status. (2021). Global Patent Database. Retrieved from [URL]
